Akari Therapeutics is a clinical-stage oncology biotechnology company developing next-generation antibody-drug conjugates (ADCs) with a novel spliceosome-targeting payload (PH1). The company's lead program, AKTX-101, is advancing toward a Phase 1 first-in-human clinical trial. Akari is listed on Nasdaq (AKTX) and operates from New York and Boston.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2025
Mar 2025
Jun 2024
Jan 2024
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Clinical-stage precision medicine company developing targeted therapies for immune-mediated infla...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
Clinical-stage biopharmaceutical developing precision medicines targeting novel mechanisms to tre...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
